Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Newcastle Disease Virus /von 2022-01-19 / Genes Immun 2022 02;23(1):1-11Oncolytic viruses: A novel treatment strategy for breast cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2021-12-16 / Genes Dis 2023 Mar;10(2):430-446Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2021-11-19 / J Clin Transl Hepatol 2022 Apr;10(2):284-296Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-10-05 / Front Immunol 2021;12:721830Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2021-10-04 / Gene Ther 2023 Feb;30(1-2):64-74Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro
/in International Publications, Newcastle Disease Virus /von 2021-07-25 / Res Vet Sci 2021 Jul;139:159-165Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
/in International Publications, Newcastle Disease Virus /von 2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
/in International Publications, Newcastle Disease Virus /von 2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de